Roche’s Tecentriq plus platinum-based chemotherapy improves PFS in bladder cancer study

This article was originally published here

The study has achieved its co-primary endpoint of investigator-assessed progression-free survival (PFS). Roche’s combination of Tecentriq plus platinum-based chemotherapy demonstrated a statistically significant reduction in the risk of

The post Roche’s Tecentriq plus platinum-based chemotherapy improves PFS in bladder cancer study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply